Allogene Therapeutics Inc (ALLO)
NASDAQ:ALLO
US Market
Holding ALLO?
Track your performance easily

Allogene Therapeutics (ALLO) Ownership - Who Owns Allogene Therapeutics?

1,302 Followers

Allogene Therapeutics (ALLO) Ownership Overview

10.23%28.98%5.30%10.68%44.80%
10.23% Insiders
5.30% Other Institutional Investors
10.68% ETFs
44.80% Public Companies and Individual Investors
The ownership structure of Allogene Therapeutics (ALLO) stock is a mix of institutional, retail, and individual investors. Approximately 44.97% of the company’s stock is owned by Institutional Investors, 10.23% is owned by Insiders, and 44.80% is owned by Public Companies and Individual Investors.
The ownership structure of {name} ({ticker}) stock is a mix of institutional, retail, and individual investors. {displayInstitutionalData, select, display {Approximately {institutionalPercentage} of the company’s stock is owned by Institutional Investors} other {}}{displayInsiderText, select, display {, {insidersPercentage} is owned by Insiders} other {}}{displayInvestorsText, select, display {, and {retailInvestorsPercentage} is owned by Public Companies and Individual Investors.} other {}}

Recent Insider Trading Activity

Date
Name
Activity
Value
Jun 03, 2024
Franz Humer
Director
xxxxxxxxxxxxx
$26096
May 20, 2024
xxxxxxxxxxxxx
$4999997
Mar 06, 2024
xxxxxxxxxxxxx
$682

Recent Hedge Fund Trading Activity

Date
Firm
Activity
Value
Jun 30, 2024
xxxxxxxxxxxxx
$1086036
Jun 30, 2024
xxxxxxxxxxxxx
$6349250
Jun 30, 2024
xxxxxxxxxxxxx
$6805433
Jun 30, 2024
xxxxxxxxxxxxx
$10156444

Top Shareholders

Holder
# of Shares
Type
% Holding
Value
10,099,279Insider4.82%31,206,772
7,945,735Institution3.79%24,552,321
7,723,302Insider3.68%23,865,003
7,035,377Institution3.36%21,739,315
6,896,552Institution3.29%21,310,346
6,880,475Institution3.28%21,260,668
6,291,585Institution3.00%19,440,998
5,772,200Institution2.75%17,836,098
5,668,260Institution2.70%17,514,923
5,039,432Institution2.40%15,571,845

Top Mutual Fund Holders

Holder
# of Shares
Type
% Holding
Value
7,035,377Institution3.36%21,739,315
6,896,552Institution3.29%21,310,346
6,880,475Institution3.28%21,260,668
5,772,200Institution2.75%17,836,098
5,039,432Institution2.40%15,571,845
4,604,376Institution2.20%14,227,522
4,271,720Institution2.04%13,199,615
3,537,479Institution1.69%10,930,810
2,059,978Institution0.98%6,365,332
1,988,965Institution0.95%6,145,902

Top ETF Holders

Holder
# of Shares
Type
% Holding
Value
4,337,709Institution2.07%12,145,585
3,562,177Institution1.70%10,971,505
3,526,181Institution1.68%10,895,899
2,470,719Institution1.18%6,918,013
1,228,669Institution0.59%3,796,587
961,416Institution0.46%2,970,775
768,747Institution0.37%2,367,741
732,884Institution0.35%2,257,283
585,908Institution0.28%1,640,542
443,748Institution0.21%1,366,744

FAQ

Who Owns Allogene Therapeutics Inc (ALLO)?
According to the latest TipRanks data, approximately 5.30% of the company's stock is held by institutional investors, 10.23% is held by insiders, and 44.80% is held by retail investors.
    What percentage of Allogene Therapeutics Inc (ALLO) stock is held by institutional investors?
    According to the latest TipRanks data, approximately 5.30% of Allogene Therapeutics Inc (ALLO) stock is held by institutional investors.
      What percentage of Allogene Therapeutics Inc (ALLO) stock is held by retail investors?
      According to the latest TipRanks data, approximately 44.80% of Allogene Therapeutics Inc (ALLO) stock is held by retail investors.
        Who owns the most shares of Allogene Therapeutics Inc (ALLO)?
        Arie Belldegrun owns the most shares of Allogene Therapeutics Inc (ALLO).
          What is the significance of the ownership structure for a publicly traded company?
          The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis